Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph not_applicable
1
14%
Ph phase_1
2
29%
Ph phase_2
1
14%
Ph phase_4
1
14%
Ph phase_3
2
29%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 21 (14.3%)
Phase 32 (28.6%)
Phase 41 (14.3%)
N/A1 (14.3%)

Trials by Status

unknown114%
enrolling_by_invitation114%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
enrolling_by_invitationphase_4

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

NCT04297592
completedphase_3

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
completedphase_1

Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections

NCT03802552
unknownphase_3

Or v IV Antibiotics for Infection

NCT04723940
completedphase_2

Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

NCT02381470
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04297592Phase 4

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Enrolling By Invitation
NCT02814916Phase 3

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
NCT03802552Phase 1

Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections

Completed
NCT04723940Phase 3

Or v IV Antibiotics for Infection

Unknown
NCT02381470Phase 2

Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

Completed
NCT02479867Phase 1

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Completed
NCT00405158Not Applicable

Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7